May 4, 2026 9:32 AM
Candel Therapeutics Inc (NASDAQ:CADL) will host a webcast and conference call on May 15 at 1pm ET to discuss extended phase 3 data for CAN-2409 in intermediate- to high-risk localized prostate cancer.
Candel Therapeutics Inc (NASDAQ:CADL) will host a webcast and conference call on May 15 at 1pm ET to discuss extended phase 3 data for CAN-2409 in intermediate- to high-risk localized prostate cancer.
The update follows an AUA 2026 presentation and will include insights from leading specialists Neal Shore, Jonathan Tward and Daniel George.
An archived replay will be available on the company’s website for 90 days.
Comments
Powered by RoundtableAn AI/DeFi-powered Enterprise Media Operating System. Learn more at Roundtable.io.© Roundtable 2026. By using this site you agree to the Terms of Use and Privacy Policy